New staph vaccine shows promise in early safety trial
NCT ID NCT06719219
First seen Oct 31, 2025 · Last updated May 23, 2026 · Updated 27 times
Summary
This early-stage study tested a new vaccine called LTB-SA7 in 129 healthy adults to see if it is safe and triggers an immune response against Staphylococcus aureus (Staph) bacteria. Participants received either the vaccine or a placebo, and researchers monitored side effects and antibody levels. The goal is to find a preferred dose for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAPHYLOCOCCUS (S.) AUREUS INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Naval Medical Research Command Clinical Trial Center
Bethesda, Maryland, 20889, United States
Conditions
Explore the condition pages connected to this study.